-
Something wrong with this record ?
Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism
A. Aido, O. Zaitseva, H. Wajant, M. Buzgo, A. Simaite
Language English Country Switzerland
Document type Journal Article
Grant support
813871
Horizon 2020
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the "activating" effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21024391
- 003
- CZ-PrNML
- 005
- 20211013133940.0
- 007
- ta
- 008
- 211006s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics13071072 $2 doi
- 035 __
- $a (PubMed)34371763
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Aido, Ahmed $u InoCure s.r.o, Department of R&D, Prumyslová 1960, 250 88 Celákovice, Czech Republic $u Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Auverahaus, Grombühlstrasse 12, 97080 Würzburg, Germany
- 245 10
- $a Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism / $c A. Aido, O. Zaitseva, H. Wajant, M. Buzgo, A. Simaite
- 520 9_
- $a Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the "activating" effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zaitseva, Olena $u Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Auverahaus, Grombühlstrasse 12, 97080 Würzburg, Germany
- 700 1_
- $a Wajant, Harald $u Division of Molecular Internal Medicine, Department of Internal Medicine II, University Hospital Würzburg, Auverahaus, Grombühlstrasse 12, 97080 Würzburg, Germany
- 700 1_
- $a Buzgo, Matej $u InoCure s.r.o, Department of R&D, Prumyslová 1960, 250 88 Celákovice, Czech Republic
- 700 1_
- $a Simaite, Aiva $u InoCure s.r.o, Department of R&D, Prumyslová 1960, 250 88 Celákovice, Czech Republic
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 7 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34371763 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20211006 $b ABA008
- 991 __
- $a 20211013133937 $b ABA008
- 999 __
- $a ind $b bmc $g 1708303 $s 1144888
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 7 $e 20210713 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a 813871 $p Horizon 2020
- LZP __
- $a Pubmed-20211006